Company & Sponsor Intelligence

Pfizer

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials28

Recruiting1

Completed17

Countries4

Therapeutic footprint

adhdalzheimersanxietydepressionepilepsymigraine_headacheneuromuscularother_psychiatrypain_neuropathyparkinsonsschizophreniastroke

Indexed studies

NCT02006290Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
parkinsons · United StatesPHASE1

NCT01028911A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease
alzheimers · United StatesPHASE1

NCT00987220Effect of Aricept on Biomarkers (Acetylcholine, sAPP Alpha) In Cerebrospinal Fluid
alzheimers · United StatesCOMPLETED

NCT03872453Acute Treatment Trial in Adult Subjects With Migraines
anxiety · United StatesPHASE2, PHASE3

NCT00562055Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.
adhd · PHASE2

NCT01372150A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
depression · United StatesPHASE3

NCT04408794Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
migraine_headache · United StatesPHASE2, PHASE3

NCT00939783An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT01353963Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
depression · PhilippinesTERMINATED

NCT04571060Randomized Trial in Adult Participants With Acute Migraines
anxiety · United StatesPHASE3

NCT00838110A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
alzheimers · United StatesPHASE3

NCT01975389The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
stroke · United StatesPHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →